Gossamer Bio advances the Feb. 2026 PROSERA Phase 3 readout for seralutinib in PAH, with expanded endpoints and a new ILD trial. Learn why GOSS stock is a hold.

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Eric's career includes extensive work in both public and corporate accounting with ...

Abstract: Biometric authentication is, over time, becoming an indispensable complementary component to traditional authentication methods that use passwords and tokens. As a result, the research ...

First Trust Senior Floating Rate Income Fund II plans ETF conversion, boosting liquidity and value for investors. Click for ...

Abstract: Recently deep neural network (DNN) has been proposed for fault diagnosis of modular multilevel converter (MMC). The training of DNN is convenient due to its end-to-end feature, and DNN has a ...